Overview

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
Phase:
Phase 1
Details
Lead Sponsor:
Takeda